Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis

Bibliography

• Stone E. Leber congenital amaurosis-a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 2007;144:791-811
   PubMed Web of Science ®Google Scholar
• den Hollander A. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008;27:391-419
   PubMed Web of Science ®Google Scholar
• Roy K, Stein L, Kaushal S. Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease. Hum Gene Ther 2010;21:915-27
   PubMed Web of Science ®Google Scholar
• Dejneka NS, Surace EM, Aleman TS, In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 2004;9:182-8
   PubMed Web of Science ®Google Scholar
• Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retinal Eye Res 2010;29:398-427
   PubMed Web of Science ®Google Scholar
• Pang JJ, Chang B, Kumar A, Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 2006;13:565-72
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Acland GM, Aguirre GD, Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006;13:1074-84
   PubMed Web of Science ®Google Scholar
• Acland GM, Aguirre GD, Ray J, Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-5
   PubMed Web of Science ®Google Scholar
• Narfstrom K, Katz ML, Ford M, In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered 2003;94:31-7
   PubMed Web of Science ®Google Scholar
• Narfstrom K, Katz ML, Bragadottir R, Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003;44:1663-72
   PubMed Web of Science ®Google Scholar
• Acland GM, Aguirre GD, Bennett J, Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005;12:1072-82
   PubMed Web of Science ®Google Scholar
• Le Meur G, Stieger K, Smith AJ, Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14:292-303
   PubMed Web of Science ®Google Scholar
• Aguirre GK, Komaromy AM, Cideciyan AV, Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 2007;4:e230
   PubMed Web of Science ®Google Scholar
• Bennett J, Maguire AM, Cideciyan AV, Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci USA 1999;96:9920-5
   PubMed Web of Science ®Google Scholar
• Le Meur G, Weber M, Pereon Y, Postsurgical assessment and long-term safety of recombinant adeno-associated virus-mediated gene transfer into the retinas of dogs and primates. Arch Ophthalmol 2005;123:500-6
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Boye SL, Aleman TS, Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006;17:845-58
   PubMed Web of Science ®Google Scholar
• Hauswirth WW, Aleman TS, Kaushal S, Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-90
   PubMed Web of Science ®Google Scholar
• Maguire AM, High KA, Auricchio A, Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374:1597-605
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Smith AJ, Barker SS, Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-9
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Hauswirth WW, Aleman TS, Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20:999-1004
   PubMed Web of Science ®Google Scholar
• Simonelli F, Maguire AM, Testa F, Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-50
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Aleman TS, Cideciyan AV, Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci USA 2007;104:15123-8
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Cideciyan AV, Aleman TS, Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 2008;49:4573-7
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Aleman TS, Boye SL, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008;105:15112-17
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Ali RR. The eyes have it! Ocular gene therapy trials for LCA look promising. Gene Ther 2008;15:1191-2
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Hauswirth WW, Aleman TS, Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009;361:725-7
   PubMed Web of Science ®Google Scholar
• Saperstein D. Synthetic retinoid treatment for Leber congenital amaurosis and related disease: preclinical and phase Ia testing of QLT091001. American Society of Retinal Specialists, poster presentation. Available from: http://www.qltinc.com/development/products/documents/ASRS2009RGXposter.pdf 2009
   Google Scholar
• Van Hooser JP, Aleman TS, He YG, Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci USA 2000;97:8623-8
   PubMed Web of Science ®Google Scholar
• Van Hooser JP, Liang Y, Maeda T, Recovery of visual functions in a mouse model of Leber congenital amaurosis. J Biol Chem 2002;277:19173-82
   PubMed Web of Science ®Google Scholar
• Batten ML, Imanishi Y, Tu DC, Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis. PLoS Med 2005;2:e333
   PubMed Web of Science ®Google Scholar
• Ablonczy Z, Crouch RK, Goletz PW, 11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors. J Biol Chem 2002;277:40491-8
   PubMed Web of Science ®Google Scholar
• Maeda T, Maeda A, Casadesus G, Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice. Invest Ophthalmol Vis Sci 2009;50:4368-78
   PubMed Web of Science ®Google Scholar
• Margaron P, Castaner L, Narfstrom K. Evaluation of intravitreal cis-retinoid replacement therapy in a canine model of Leber's congenital amaurosis. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, E-Abstract, poster presentation. Available from: http:www.qltinc.com/development/products/documents/ARVO2009Poster.pdf 2009
   Google Scholar
• Gearhart P, Gearhart C, Thompson D, Petersen-Jones S. Improvement of visual performance with intravitreal administration of 9-cis-retinal in rpe65-mutant dogs. Arch Ophthalmol 2010;128:1483-5
   PubMed Web of Science ®Google Scholar
• QLT, Inc. New products in site, corporate presentation. 2010. p. 24
   Google Scholar
• Drugs.com. QLT announces completion of Phase Ia safety trial of its synthetic retinoid product. Available from: http://drugs.com/clinical_trials/qlt-announces-completion-phase-ia-safety-trial-synthetic-retinoid-product-6859.html 2009
   Google Scholar
• The Foundation for Fighting Blindness. Canadian-led study holds promise for patients living with a progrssive form of blindness, May 26, 2010. Available from: http://www.ffb.ca/news/immediate_release.html 2010
   Google Scholar
• Clinical Trials.gov. A safety/proof of concept study to evaluate the effects of oral QLT091001 in subjects with Leber congenital amaurosis (LCA) due to RPE65 or LRAT mutations. Available from: http://clinicaltrials.gov/ct2/show/NCT01014052?term=NCT01014052&rank=1 2010
   Google Scholar
• Jacobson SG, Acland GM, Aguirre GD, Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006;13:1074-84
   PubMed Web of Science ®Google Scholar